Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Europe fast-tracking swine flu vaccine
Associated Press
LONDON – In a drive to inoculate people against swine flu before winter, many European governments say they will fast-track the testing of a new flu vaccine, arousing concern among some experts about safety issues and proper vaccine doses.
The European Medicines Agency, the EU's top drug regulatory body, is accelerating the approval process for swine flu vaccine, and countries such as Britain, Greece, France and Sweden say they'll start using the vaccine after it's greenlighted — possibly within weeks.
In an interview with The Associated Press, Dr. Keiji Fukuda, the World Health Organization's flu chief, warned about the potential dangers of untested vaccines, although he stopped short of criticizing Europe's approach outright.
"One of the things which cannot be compromised is the safety of vaccines," he said Friday. "There are certain areas where you can make economies, perhaps, but certain areas where you simply do not try to make any economies."
Flu vaccines have been used for 40 years, and many experts say extensive testing is unnecessary, since the swine flu vaccine will simply contain a new ingredient: the swine flu virus.
But European officials won't know if the new vaccine causes any rare side effects until millions of people get the shots. Still, they say the benefit of saving lives is worth the gamble.
"Everybody is doing the best they can in a situation which is far from ideal," said Martin Harvey-Allchurch, a spokesman for the European Medicines Agency. "With the winter flu season approaching, we need to make sure the vaccine is available."
In Europe, flu vaccines are usually tested on hundreds of people for several weeks or months, to ensure the immune system produces enough antibodies to fight the infection.
But to ensure swine flu vaccine is available as soon as possible, the European Medicines Agency is allowing companies to skip testing in large numbers of people before the vaccine is approved.
The main issue is probably that without thorough testing it's difficult to gauge the effective dosage — meaning Europeans might get too weak a vaccine. It's unlikely the vaccine would endanger anyone, but until it is used in large numbers of people, no one will know for sure.
Europeans appear ready to use the vaccine widely before conducting any big studies to prove it is safe and effective. Neither the vaccine makers nor the European Medicines Agency would specify what basic safety tests are being done.
The U.S. is taking a more cautious approach: the government called Wednesday for several thousand volunteers to be injected with the swine flu vaccine in tests beginning in August to assess the vaccine's safety. American officials said results should be ready by the time the U.S. plans to roll out a vaccination campaign in October.
Results from the U.S. tests will be of limited use to Europe, since countries like Britain plan to start vaccinating as early as August — before any American trial data is available. The vaccines used in the U.S. will also be different from those in Europe.
Some experts favor urgent action.
"The consequences of not having a vaccine if this virus gets worse are very high," said Leonard Marcus, a public health expert at Harvard University. "If (regulatory authorities) took all the time that was necessary to make sure there are no side effects, ironically, in the effort to save a few lives, many lives could be lost."
But critics say dangers lurk in any strategy to vaccinate without robust testing.
Scant information exists on flu vaccines with adjuvants, a component used to stretch the active ingredient that is commonly found in European flu vaccines. There are no licensed flu vaccines with the ingredient in the U.S.
There is also limited or no data on the safety and effectiveness of vaccines with adjuvants in children under 3 and pregnant women — two of the most vulnerable groups in a pandemic — a global outbreak.
Mass swine flu vaccination campaigns will also take place in the shadow of the 1976 swine flu disaster, when hundreds of people in the U.S. developed Guillain-Barre syndrome, a paralyzing disorder, after being vaccinated.
Experts don't know why that happened, but say modern vaccine production techniques have improved since 1976. To avoid a similar episode, some say comprehensive testing before the vaccine is rolled out is essential.
"I can't see any possible excuse to not test it for safety before it's given to anyone," said George Annas, a bioethics expert at Boston University.
If the vaccine turns out to have dangerous side effects, it could generate a public backlash, particularly in a country like Britain, where many people remain suspicious of vaccines because of unsubstantiated allegations linking the measles, mumps and rubella vaccine to autism. That could lead to millions of people refusing vaccination.
When the bird flu crisis hit several years ago, the European Medicines Agency designed a special protocol to approve a vaccine for use in a pandemic as soon as possible.
The agency let companies submit data for a "mock-up" vaccine, using H5N1 bird flu. The idea was to do most of the testing before the global epidemic hit so when it did, drugmakers could insert the pandemic virus into the vaccine at the last minute.
When the first swine flu vaccine doses are ready, the European Medicines Agency will approve them largely based on data from the bird flu vaccine, since both will have the same basic ingredients.
If the agency thinks the bird flu data predicts how the swine flu virus will work, they will approve it, said spokesman Harvey-Allchurch.
The agency will then require regular reporting of the vaccine's effects as it is being administered — monitoring that is normally done beforehand.
WHO's Fukuda said everyone involved in making the vaccine, from manufacturers to regulatory agencies, is looking at what steps can be taken to streamline the process.
"But there is no one who disagrees that one of the absolutes is that there can't be any question whether the vaccine is safe or not," he said.
WHO reported that the swine flu viruses aren't producing enough of a key vaccine ingredient, which may limit how much vaccine is available. Its laboratory network is now working to produce a new set of viruses that it hopes will work better.
Drugmakers including Baxter International, GlaxoSmithKline PLC, Novartis and Sanofi-Pasteur, however, insist they will be able to start shipping the first batches of vaccine soon.
British health officials have repeatedly said they will start vaccinating in August, as soon as the vaccine is approved. Other European countries, including Greece, France, Sweden, say they will use the vaccine after it gets the green light from the European agency, but none other than Britain expect to start the shots next month.
___
Associated Press writers Frank Jordans in Geneva, Malin Rising in Stockholm, Jenny Barchfield in Paris, and Derek Gatopoulos in Athens contributed to this report.
http://news.yahoo.com/s/ap/20090726/ap_on_he_me/eu_med_swine_flu_vaccine_fast_track
Europe fast-tracking swine flu vaccine
Associated Press
LONDON – In a drive to inoculate people against swine flu before winter, many European governments say they will fast-track the testing of a new flu vaccine, arousing concern among some experts about safety issues and proper vaccine doses.
The European Medicines Agency, the EU's top drug regulatory body, is accelerating the approval process for swine flu vaccine, and countries such as Britain, Greece, France and Sweden say they'll start using the vaccine after it's greenlighted — possibly within weeks.
In an interview with The Associated Press, Dr. Keiji Fukuda, the World Health Organization's flu chief, warned about the potential dangers of untested vaccines, although he stopped short of criticizing Europe's approach outright.
"One of the things which cannot be compromised is the safety of vaccines," he said Friday. "There are certain areas where you can make economies, perhaps, but certain areas where you simply do not try to make any economies."
Flu vaccines have been used for 40 years, and many experts say extensive testing is unnecessary, since the swine flu vaccine will simply contain a new ingredient: the swine flu virus.
But European officials won't know if the new vaccine causes any rare side effects until millions of people get the shots. Still, they say the benefit of saving lives is worth the gamble.
"Everybody is doing the best they can in a situation which is far from ideal," said Martin Harvey-Allchurch, a spokesman for the European Medicines Agency. "With the winter flu season approaching, we need to make sure the vaccine is available."
In Europe, flu vaccines are usually tested on hundreds of people for several weeks or months, to ensure the immune system produces enough antibodies to fight the infection.
But to ensure swine flu vaccine is available as soon as possible, the European Medicines Agency is allowing companies to skip testing in large numbers of people before the vaccine is approved.
The main issue is probably that without thorough testing it's difficult to gauge the effective dosage — meaning Europeans might get too weak a vaccine. It's unlikely the vaccine would endanger anyone, but until it is used in large numbers of people, no one will know for sure.
Europeans appear ready to use the vaccine widely before conducting any big studies to prove it is safe and effective. Neither the vaccine makers nor the European Medicines Agency would specify what basic safety tests are being done.
The U.S. is taking a more cautious approach: the government called Wednesday for several thousand volunteers to be injected with the swine flu vaccine in tests beginning in August to assess the vaccine's safety. American officials said results should be ready by the time the U.S. plans to roll out a vaccination campaign in October.
Results from the U.S. tests will be of limited use to Europe, since countries like Britain plan to start vaccinating as early as August — before any American trial data is available. The vaccines used in the U.S. will also be different from those in Europe.
Some experts favor urgent action.
"The consequences of not having a vaccine if this virus gets worse are very high," said Leonard Marcus, a public health expert at Harvard University. "If (regulatory authorities) took all the time that was necessary to make sure there are no side effects, ironically, in the effort to save a few lives, many lives could be lost."
But critics say dangers lurk in any strategy to vaccinate without robust testing.
Scant information exists on flu vaccines with adjuvants, a component used to stretch the active ingredient that is commonly found in European flu vaccines. There are no licensed flu vaccines with the ingredient in the U.S.
There is also limited or no data on the safety and effectiveness of vaccines with adjuvants in children under 3 and pregnant women — two of the most vulnerable groups in a pandemic — a global outbreak.
Mass swine flu vaccination campaigns will also take place in the shadow of the 1976 swine flu disaster, when hundreds of people in the U.S. developed Guillain-Barre syndrome, a paralyzing disorder, after being vaccinated.
Experts don't know why that happened, but say modern vaccine production techniques have improved since 1976. To avoid a similar episode, some say comprehensive testing before the vaccine is rolled out is essential.
"I can't see any possible excuse to not test it for safety before it's given to anyone," said George Annas, a bioethics expert at Boston University.
If the vaccine turns out to have dangerous side effects, it could generate a public backlash, particularly in a country like Britain, where many people remain suspicious of vaccines because of unsubstantiated allegations linking the measles, mumps and rubella vaccine to autism. That could lead to millions of people refusing vaccination.
When the bird flu crisis hit several years ago, the European Medicines Agency designed a special protocol to approve a vaccine for use in a pandemic as soon as possible.
The agency let companies submit data for a "mock-up" vaccine, using H5N1 bird flu. The idea was to do most of the testing before the global epidemic hit so when it did, drugmakers could insert the pandemic virus into the vaccine at the last minute.
When the first swine flu vaccine doses are ready, the European Medicines Agency will approve them largely based on data from the bird flu vaccine, since both will have the same basic ingredients.
If the agency thinks the bird flu data predicts how the swine flu virus will work, they will approve it, said spokesman Harvey-Allchurch.
The agency will then require regular reporting of the vaccine's effects as it is being administered — monitoring that is normally done beforehand.
WHO's Fukuda said everyone involved in making the vaccine, from manufacturers to regulatory agencies, is looking at what steps can be taken to streamline the process.
"But there is no one who disagrees that one of the absolutes is that there can't be any question whether the vaccine is safe or not," he said.
WHO reported that the swine flu viruses aren't producing enough of a key vaccine ingredient, which may limit how much vaccine is available. Its laboratory network is now working to produce a new set of viruses that it hopes will work better.
Drugmakers including Baxter International, GlaxoSmithKline PLC, Novartis and Sanofi-Pasteur, however, insist they will be able to start shipping the first batches of vaccine soon.
British health officials have repeatedly said they will start vaccinating in August, as soon as the vaccine is approved. Other European countries, including Greece, France, Sweden, say they will use the vaccine after it gets the green light from the European agency, but none other than Britain expect to start the shots next month.
___
Associated Press writers Frank Jordans in Geneva, Malin Rising in Stockholm, Jenny Barchfield in Paris, and Derek Gatopoulos in Athens contributed to this report.
Sheff- Not a "One Trick Pony " @ BIEL
Reading your post here clearly highlights a company that is well diversified with several medical accomplishments other that the Allay Period Relief Patch.
Interesting notes from the previous conference call discussion looks terrific so Tuesday call could be what I call a "WOW" factor in how much more has been accomplished with new updates!
With all the medical activity given I am surprised the PPS trades in pennies (.055-.0665 ) but expect that to change as well as move to another board perhaps AMEX / NASD and of course partnerships that could also be of interest.
Pleased to be on-board @ BIEL and thanks for the excellent DD you have provided that made it easy to take a position!
Much success to all that have shares and still an opportunity for those that have not!
Investor 100
Swine flu fears prompt run on UK pharmacies
CNN Health.com
LONDON, England (CNN) -- Pharmacies in England are reporting a run on supplies like surgical masks, thermometers and anti-bacterial gels by customers concerned about swine flu amid a surge in the number of people infected by the virus.
A box of leaflets containing information about swine flu, distributed by the UK's Department of Health.
A box of leaflets containing information about swine flu, distributed by the UK's Department of Health.
In some cases, drug stores in England say they are out of the items and may not get more in for weeks or months.
"People are very panicked," said a pharmacy assistant at Zafash Pharmacy in southwest London. "That's why everyone is running for thermometers, surgical masks, and anti-bacterial gels."
The UK's Department of Health estimated this week that there were around 100,000 new cases of swine flu in England in the week ending July 17 -- nearly double the number of cases for the previous seven days.
The UK has been hit hard by the H1N1 virus, with only the U.S. and Mexico recording more cases of infection, according to World Health Organization figures earlier this month.
The World Health Organization has stopped giving a global tally of cases but said Friday that swine flu has now spread to more than 160 areas and territories in the world.
At least 26 people have died of the disease and this week the British government set up a national flu hot line and Web site to allow those suspected of having swine flu to get a prescription for antiviral medication over the phone.
Those who are given prescriptions must pick up the medication at designated collection points in their area.
But at Hodgetts Chemist in north London, a supply of surgical masks that normally lasts for half a year has gone in three days, said pharmacy assistant Sylwia Sznyk.
Don't Miss
* New swine flu cases double to 100,000 in UK
* Poisoned chalice? Swine flu hits church wine
* U.S. trials for H1N1 vaccine announced
* Swine flu facts
Sznyk displayed a receipt from the chemist's suppliers that showed three types of digital thermometers that were out of stock. The pharmacy is now out of thermometers.
"One of the manufacturers, he said the next thermometers they will have is in October, so now there is no chance to get them from this particular supplier," she told CNN.
The supplier is also out of stock of three different types of anti-bacterial gel, she said, even though the gel is ineffective against viruses.
Central Pharmacy in Ashington, in northern England, is also out of thermometers, pharmacist Nadeem Shah told CNN. He said he believes most shops and pharmacies in the area are also out.
"There's no thermometers at all, which is worrying because it's just a sign that it's going to impact on other supplies as well linked to people generally not feeling well -- in particular paracetamol (acetaminophen), ibuprofen, and other medications," Shah said.
The pharmacy was out of stock of anti-bacterial gels last month, but manufacturers are making more so it's back on the shelf, he said. However, it's being sold for nearly double the price, he said.
"They're pennies otherwise to buy, but very quickly some manufacturers have got into the market of producing gels and their prices are quite high," Shah said.
At their sister pharmacy in nearby Morpeth, any anti-bacterial products at the checkout counter are "gone in a day, rather than in a month," he said.
"Some of the gels don't do anything different to your soap at home," he said, emphasizing that good hygiene, good handwashing, and disposable tissues are the best way to ward off viral infection.
"There's definitely some kind of misunderstanding -- people are thinking that having those type of products will give them a bit more confidence. But it's their choice, obviously."
Though Central Pharmacy does not normally sell surgical masks, they considered stocking some when the virus broke out a few months ago, Shah said. They decided against it so as not to stoke panic.
"It could be seen as a sign of endorsement rather than asking people to get advice," he said. "It would just give a very visible panic message."
Croydon Pharmacy, south of London, still has stocks of thermometers despite higher demand, but it has run out of surgical masks, said pharmacist Michael Hammond. He said the pharmacy has noticed a rise in people asking questions and wanting information about swine flu.
"I think the reaction has been in response to what they've heard on the news," Hammond said. "And even where it is not a true case of the patient suffering, they still want more information. But I think generally we've been able to give them what they need."
A branch of the Boots pharmacy chain in Fulham, southwest London, has been out of thermometers for two weeks, said employee Wilson Le. They're also running out of anti-bacterial gels; the store doesn't stock surgical masks.
While it is not running out yet, one pharmacy in the eastern English city of Norwich said it is noticing an increase in demand for masks, thermometers, and anti-bacterial items.
"It's not completely a foregone situation where I can't get hold of it, but it's becoming difficult," said the pharmacist, who asked not to be identified because his pharmacy is one of the government's distribution points for the antiviral medication Tamiflu, and he didn't want to spark concern.
The pharmacist said he was doling out Tamiflu to 70 to 80 people a day and described the lack of supplies as worrying.
"From a business point of view, yes, and from a clinical point of view, yes, because I can't offer the services I need to," he said. "And if people want reassurance from (the supplies), I'm not able to reassure them."
The pharmacist complained that the paperwork he is required to fill out for each patient takes him five minutes per person, giving him less time to spend consulting with other customers.
"I wish somebody would have organized it a little bit better," the pharmacist said.
Shah, of Central Pharmacy, said the run on supplies makes him worry that they won't be available later in the year, when flu season kicks in.
"Manufacturers would have made their plans for winter a while ago, but if we're consuming these products early, in August and July, I don't know if those manufacturing plans are in place yet," he said.
The government advises anyone suspected of having swine flu to send a friend or relative -- a "flu friend" -- to their pharmacy to pick up the medicine for them. But that advice isn't being followed by everyone.
"Some patients come in directly rather than ask their friend to come," said Le, of Boots pharmacy in Fulham. He said one dispenser has come down with swine flu after being infected by a sick customer.
http://www.cnn.com/2009/HEALTH/07/25/uk.swine.flu.pharmacies/index.html
Hot Stock Alerts
No surprise to see BIEL on the list given all the positive news posted as we lead up to Tuesday's CC.
--------------------------------------------------
Friday, July 24, 2009
Top Most Active OTC Pink Sheets Stocks - 7/27/09
The following is a list of the Most Popular OTC, OTCBB, Pink Sheets Stocks going into July 27, 2009. Topping the list again is the Old General Motors Corp. This list shows you which stocks traders and investors consider " Hot " which makes for great trading.
Stocks Highlighed in Green were Up on the day.
1. Motors Liquidation Company (MTLQQ.PK)
2. SpongeTech Delivery Systems, Inc. (SPNG.OB)
3. BioElectronics Corporation (BIEL.PK)
4. Cobra Oil & Gas Company (CGCA.OB)
5. Advanced Life Sciences Holdings, Inc. (ADLS.OB)
6. LIFELINE BIOTECH (LLBO.PK)
7. New Energy Technologies, Inc. (NENE.OB)
8. Sarissa Resources, Inc. (SRSR.PK)
9. ZAGG Incorporated (ZAGG.OB)
10. Electronic Game Card Inc. (EGMI.OB)
11. NESTLE SA REG SHRS S (NSRGY.PK)
12. RESOURCE GROUP INTL (RSGR.PK)
13. General Growth Properties Inc. (GGWPQ.PK)
14. EXPO HOLDING INC (EXPH.PK)
15. Evolution Fuels, Inc. (EVFL.PK)
16. Ingen Technologies, Inc. (IGNT.PK)
17. KODIAK ENERGY INC (KDKN.OB)
18. CHINA DIGITAL COMM (CMTP.OB)
19. Celsius Holdings, Inc. (CSUH.OB)
20. Neogenomics Inc. (NGNM.OB)
http://daytradingstockblog.blogspot.com/2009/07/top-most-active-otc-pink-sheets-stocks.html
GLTA
Investor 100
You to fourkids.
Investor 100
HOD @ BIEL
.063
Good weekend the Sheff & board posters!
Investor 100
Stockcharts.com @ BIEL
http://stockcharts.com/charts/gallery.html?s=biel
Its has been steady all week and still has room for growth!
Good for those to take initial position or add position.
GLTA
Investor 100
Yes, that has a nice ring to it.
Like to add more if we see a dip before Tuesday's CC.
GLTA
Investor 100
Thank you Sheff!
With your alert and DD I would have missed this opportunity!
Pleased to be holding BIEL with high hopes in weeks and months ahead.
Other holdings- BDSI-DDSS-HEB
GLTA
Investor 100
You Tube @ BIEL
You Tube @ BIEL
Thanks Sheff..
Solid news going into Tuesday's cc call perhaps a "WOW moment.
GLTA
Investor 100
Nice Progress report before the CC @ Tuesday!
Look forward to more information as we move forward Sheff!
" No reverse split or reverse merger contemplated " I like it.
Looking to add a few more too:)
GLTA
Investor 100
Nanotechnology Perspective
http://www.azonano.com/news.asp?NewsID=8856
Mind you the date-Nov 2008
GLTA
Investor 100
Took advantage of the dip @ BIEL
Added another 100K late yesterday @ .053
Solid DD completed by Sheff- Thanks!
Holdings 250K
GLTA
Investor 100
New swine flu cases double to 100,000 in UK
CNN Health- updated 3 hours, 57 minutes ago
LONDON, England (CNN) -- There were 100,000 new cases of swine flu in England last week, nearly double the number from the previous seven days, authorities announced Friday.
A person enters a clinic in east London.
A person enters a clinic in east London.
Children 14 or younger were those predominantly affected, with those older than 65 showing much lower rates, the Department of Health said in its weekly swine flu update.
Most cases continue to be mild, the department said, but a small minority are severe.
The last weekly update showed 55,000 new cases. There is no figure for the week before that, but for the week ended July 3, there were 2,798 new cases. There were 1,442 new cases the week before that, according to department figures.
The Department of Health obtained the data from doctor's offices that report their consultations for flu-like or other acute respiratory illnesses. It said consultation rates at doctor's offices had risen sharply in the past week.
There are 840 patients hospitalized with swine flu in England, the department said.
The number of deaths related to swine flu is 26. That figure is the same as the week before, because some unrelated deaths were removed from the tally and others were added, the department said.
The death toll accounts for the number of people with swine flu who died, rather than the number of deaths solely attributable to swine flu, the department said.
Britain launched a service Thursday to give people advice about swine flu over the Internet and over the phone, and allow them to get antiviral medication if they show symptoms.
Don't Miss
* U.S. trials for H1N1 vaccine announced
* Swine flu facts
* Poisoned chalice? Swine flu hits church wine
* Australia to begin first human test of swine flu vaccine
In its first day of operation, the Web site experienced unprecedented demand, the department said, with 2,600 hits per second, or 9.3 million hits per hour. Video Watch how Web site was overwhelmed »
The site did not crash, the department said, but it had to ask Internet service provider BT to quadruple capacity.
Workers at the call centers are not medical professionals, but are trained to ask callers a series of questions about their symptoms.
If a caller has symptoms, he gets a unique access number and is told where the nearest antiviral collection point is. He is then advised to ask a friend or relative -- a "flu friend" -- to pick up the medication for him.
advertisement
The government advises people who suspect they have swine flu not to go to their doctor or an emergency room unless their condition worsens or lasts a long time, or if they are pregnant, have a child younger than 1, or have a serious underlying illness.
"The National Pandemic Flu Service will give patients access to information and antivirals as quickly as possible," Health Secretary Andy Burnham said. "It will free up (doctors) so they can focus their efforts on helping those in at risk groups and patients with other illnesses."
Reviewing the tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248441799&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
Interesting Report on Oil
http://www.cnbc.com/id/32107761
Looks as thou we have a ways to go on the recovery.
GLTA
Investor 100
Stock BB Market Blog Digest
BIEL - More Gains Today
BIEL continued its bullish rampage today, following the big board surge, and climbed to an all-time high of $.0665 well off it low of $.0011 in Early May. The action today could have very well been the top of the over all move in the stock.
Below is the news from Wednesday:
BioElectronics to Hold Conference Call to Discuss Clinical Data Results and Status of FDA Filings
Dr. David G. Genecov to Present Results of a Clinical Study and Management Team to Provide Update on Corporate Activities, Other Clinical Studies, Distribution and FDA Filings
FREDERICK, MD, Jul 22, 2009 (MARKETWIRE via COMTEX) -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced a conference call will be held at 11AM (EDT), Tuesday, July 28th to discuss the results of a clinical study recently completed under the direction of David G. Genecov, M.D. FACS FAAP and Joel Brook, DPM, MS, FACFAS. The management team will also provide its stakeholders with an update on corporate activities and information on the status of FDA filings.
"We are very excited about the completion of this important study and we look forward to discussing the results. We thank Dr. Genecov and Dr. Brook and the many other physician primary investigators who are working diligently to determine the efficacy and safety of our patented, portable PEMF technology," commented Andrew Whelan, CEO of BioElectronics. "On our last call we had over 550 investors attempt to access the call, which overwhelmed the capacity of the conference bridge. We have ensured that all who attempt to access next week's call will be able to hear Dr. Genecov and the management team provide the latest information on the exciting developments at our company. We will also be available to answer your questions after the formal presentations have been completed."
To access the call, dial (888) 296-4217 five to ten minutes before the start time. You may be asked for passcode 4461002. There will be a replay of the call available for seven days, which can be accessed by dialing (888)203-1112 and entering passcode 4461002. Those seeking to access the call or recording from outside the U.S. should contract the Company for dial instructions.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Read more about Dr. Genecov at the following link: http://www.genecovplasticsurgery.com/images/CV_genecov.pdf
Read more about Dr. Brook at the flowing link: http://www.dallaspodiatryworks.com/about.html
Reviewing the tape @ 4pm
http://ih.advfn.com/p.php?pid=trades&cb=1248384134&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
6M looks like AF..hmm
Added myself another 100K - holding 250K
GLTA
Investor 100
BioElectronics Corporation (OTC:BIEL) is the Highest Volume Gainers Among OTC Stocks During Morning Trading Hours
BioElectronics Corporation (OTC:BIEL) is moving up on very unusual volume. It surged 15% at $0.0600 and traded over 12.95 million shares. Yesterday July 23, BioElectronics Corp. , the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced a conference call will be held at 11AM (EDT), Tuesday, July 28th to discuss the results of a clinical study recently completed under the direction of David G. Genecov, M.D. FACS FAAP and Joel Brook, DPM, MS, FACFAS. The management team will also provide its stakeholders with an update on corporate activities and information on the status of FDA filings.
http://www.tradingmarkets.com/.site/news/Stock%20News/2437865/
GLTA
Investor 100
BDSI wins $27 million milestone payment from Meda
Thu. July 23, 2009; Posted: 09:51 AM
Jul 23, 2009 (Datamonitor via COMTEX) -- BDSI | Quote | Chart | News | PowerRating -- BioDelivery Sciences International, a US-based specialty pharmaceutical company, has received $26.7 million in milestone payments
from its commercial partner Meda, a Swedish specialty pharmaceutical company, in connection with the approval by the FDA of BDSI's breakthrough cancer pain product Onsolis and satisfactory preparation of commercial launch supplies.
In addition to the $26.7 million received, BioDelivery Sciences International (BDSI) will also receive a double-digit royalty on net sales of Onsolis, and the potential for additional milestone payments of up to another $30 million upon the achievement of certain sales thresholds.
Onsolis will be commercialized in the US by Meda Pharmaceuticals, the US subsidiary of Meda and is expected to be available for sale early fourth quarter of 2009.
Mark Sirgo, president and CEO of BDSI, said: "The receipt of this milestone payment, together with approximately $5 million we have received from the exercise of outstanding warrants over the past several weeks, puts the company in the strongest financial position in its history, with approximately $30 million in cash and no long term debt.
"These funds allow us to immediately turn to accelerating the development of our exciting pipeline, particularly Bema buprenorphine and Bioral amphotericin B, as well as to place a third Bema product in the clinic in 2010."
http://www.tradingmarkets.com/.site/news/Stock%20News/2437756/
GLTA
Investor 100
Moving like a rocket investor911
terrific gains the past 2 days...missed it.
Investor 100
HOD @ BDSI
$5.60
GLTA
Investor 100
Could be the pending DDSS response-hotdog
The API manufacturer, Angelini, has informed Labopharm that, further to the FDA's complete response letter to Labopharm, in which the FDA raises observations concerning the Drug Master File (DMF) holder in the section "Facility Inspections", Angelini can confirm that the observations raised by the FDA are not critical and that it has not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends to address the observations raised by the FDA in an action plan that Angelini is going to submit to the FDA by July 24, 2009.
"We intend to work closely with the FDA and Angelini to resolve these issues as rapidly as possible," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We continue to prepare for the commercialization of our novel antidepressant and intend to launch in the U.S. market as soon as possible after we receive approval."
HOD @ BIEL
Lots of strength this morning @ .0665.
GLTA
Investor 100
HOD @ DDSS
$2.05
Investor 100
Stockcharts.com @ BIEL
http://stockcharts.com/charts/gallery.html?s=biel
Gotta like the MOMO.
Investor 100
Morning Sheff!
MOMO continues at BIEL this morning.
PPS .061 with high at .065.
Conference call Tuesday should be interesting.
Trying to buy a few more shares on a dip.
GLTA
Investor 100
Swine flu drug sales soar amid stockpiling
CNN NEWS:
http://www.cnn.com/2009/TRAVEL/07/22/swine.flu.drugs/index.html
Swine flu has spread so rapidly and extensively around the globe that the WHO is changing tactics against the H1N1 virus, including stopping a tally of cases and focusing on unusual patterns.
"At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable," the WHO said.
WHO declared the virus a global pandemic on June 11. More than 120 countries have reported cases of human infection, totaling more than 98,000 documented cases worldwide.
More than 700 people have died of the virus, the organization said Tuesday.
What role/participation will HEM play is a flip of the coin but the severity in its prediction clearly warrants the help from all companies involved to help (IMO).
Investor 100
Tamiflu-resistant swine flu case seen in Canada
Case is fifth of its type reported globally since the outbreak in April
This article confirms CEO Carters comments regarding Tamiflu results ( lack therof).
--------------------------------------------------------
TORONTO - Canada has recorded its first case of Tamiflu-resistant swine flu virus in a man who had been given the drug to prevent infection.
The 60-year-old Quebec man was given the flu antiviral after his son fell ill with the pandemic virus.
Jirina Vlk, spokeswoman for the Public Health Agency of Canada, says the strain does not appear to have spread beyond the reported individual case.
Use of Tamiflu to prevent infection has occasionally given rise to resistant viruses.
The Tamiflu-resistant case is the fifth reported globally since the virus was detected in April. Denmark, Hong Kong and Japan earlier reported one case each. Japan reported its second such case Tuesday, according to GenBank, a public-access library for virus sequences managed by the U.S. National Institutes of Health.
http://www.msnbc.msn.com/id/32087502/ns/health-swine_flu/
Investor 100
Solid final purchase @ BIEL today
http://ih.advfn.com/p.php?pid=trades&cb=1248294292&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
More than just a few pennies ( 3M / $155,400 ) :)
GLTA
Investor 100
Looking at the tape -DPDW
http://ih.advfn.com/p.php?pid=trades&cb=1248294549&symbol=DPDW&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
Some big plays on the tape
http://ih.advfn.com/p.php?pid=trades&cb=1248294292&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
More than just a few pennies (LOL)
Investor 100
Alan0701
Much success to you on this one.
Investor 100
That is correct bgseth.
Yes, the data thus far is positive and that "sometime" in August and update would be provided ( looking at my notes).
There are a lot of irons in the fire and this comment was one of many I picked up as very reassuring as we move forward.
Investor 100
That is correct bgseth.
Yes, the data thus far is positive and that "sometime" in August and update would be provided ( looking at my notes).
There are a lot of irons in the fire and this comment was one of many I picked up as very reassuring as we move forward.
Investor 100
Little MOMO @ HEB
Nice rally this afternoon.
Go HEB
Investor 100
Interesting Blog Comment @ BIEL
http://stockbb.net/2009/07/21/biel-another-pennystockguru-winner/
Stock is sure acting like a winner - glad to be here!
GLTA
Investor 100